Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
NLRP12 Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS: 1
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P, E |
|---|---|
| Primary Accession | P59046 |
| Other Accession | NP_653288.1, NP_150639.1 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 120173 Da |
| Antigen Region | 183-212 aa |
| Gene ID | 91662 |
|---|---|
| Other Names | NACHT, LRR and PYD domains-containing protein 12, Monarch-1, PYRIN-containing APAF1-like protein 7, Regulated by nitric oxide, NLRP12, NALP12, PYPAF7, RNO |
| Target/Specificity | This NLRP12 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 183-212 amino acids from the N-terminal region of human NLRP12. |
| Dilution | WB~~1:1000 IHC-P~~1:10~50 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | NLRP12 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | NLRP12 |
|---|---|
| Synonyms | NALP12, PYPAF7, RNO |
| Function | Plays an essential role as an potent mitigator of inflammation (PubMed:30559449). Primarily expressed in dendritic cells and macrophages, inhibits both canonical and non-canonical NF-kappa-B and ERK activation pathways (PubMed:15489334, PubMed:17947705). Functions as a negative regulator of NOD2 by targeting it to degradation via the proteasome pathway (PubMed:30559449). In turn, promotes bacterial tolerance (PubMed:30559449). Inhibits also the RIGI- mediated immune signaling against RNA viruses by reducing the E3 ubiquitin ligase TRIM25-mediated 'Lys-63'-linked RIGI activation but enhancing the E3 ubiquitin ligase RNF125-mediated 'Lys-48'-linked RIGI degradation (PubMed:30902577). Acts also as a negative regulator of inflammatory response to mitigate obesity and obesity-associated diseases in adipose tissue (By similarity). |
| Cellular Location | Cytoplasm. |
| Tissue Location | Detected only in peripheral blood leukocytes, predominantly in eosinophils and granulocytes, and at lower levels in monocytes. |
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a member of the CATERPILLER family of cytoplasmic proteins. The encoded protein, which contains an N-terminal pyrin domain, a NACHT domain, a NACHT-associated domain, and a C-terminus leucine-rich repeat region, functions as an attenuating factor of inflammation by suppressing inflammatory responses in activated monocytes. Alternatively spliced transcript variants encoding distinct isoforms have been described but the full-length nature of some of these has not been determined.
References
Bailey, S.D., et al. Diabetes Care (2010) In press :
Cummings, J.R., et al. Tissue Antigens 76(1):48-56(2010)
Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
Fahy, R.J., et al. Am. J. Respir. Crit. Care Med. 177(9):983-988(2008)
Jeru, I., et al. Proc. Natl. Acad. Sci. U.S.A. 105(5):1614-1619(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
